Yarosslavl Clinical Hospital #3
Yaroslavl, 150007, Russia
NCT Number: NCT03458208
Bioequivalence Study of 2 formulation of metformin (Metformin GEROPHARM vers. Glucophage® Merck )
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Yaroslavl, 150007, Russia
Study to evaluate the bioequivalence of orally administered metformin preparations, immediate release tablets, 1 000 mg in normal healthy subjects under fasting and fed conditions
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
First aIntervention Period:
Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition
Other names: fasting condition
Second Intervention Period:
Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition
Other names: fasting condition
Time frame: 0 hours (pre-dose), as well as at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, and 26 hours post-dose
Pharmacokinetics of metformin by Assessment of Observed Maximum Plasma Concentration (Cmax)
Time frame: 0 hours (pre-dose), as well as at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, and 26 hours post-dose
Pharmacokinetics of metformin by Assessment of Area Under the Curve From Time Zero Extrapolated to "t" (AUC(0-t))
Geropharm
Industry
Four-way Crossover, Open-label, Single-dose, Bioequivalence Study of Metformin (LLC "GEROPHARM", Russia) 1000 mg Tablets Immediate Release (IR )Versus Glucophage® (Merck Sante S.A.S, France) 1000 mg Tablets IR in Normal Healthy Subjects Under Fasting and Fed Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03452306
Behavior, Bioequivalence
Yaroslavl, Russia
View Trial DetailsNCT04101370
Behavior, Bioequivalence
Yaroslavl, Russia
View Trial DetailsNCT07698288
Bioequivalence
Mexico City, Mexico
View Trial DetailsNCT06987773
Bioequivalence
Toronto, Ontario, Canada
View Trial Details